Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663398 | 0.83 | TRPV1 (0.72) | TRPV1ALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL1663858 | 0.82 | TRPV1 (0.55) | NPC1TRPV1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL1663040 | 0.79 | ESR1 (0.55) | NPC1TRPV1TP53SMN1; SMN2KDM4E | |
| SCHEMBL10446394 | 0.79 | TRPV1 (0.52) | TRPV1ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL11931941 | 0.76 | TRPV1 (0.52) | NPC1TRPV1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL10445914 | 0.76 | TRPV1 (0.48) | TRPV1SMN1; SMN2ESR1ESR2 | |
| SCHEMBL1665830 | 0.75 | TRPV1 (0.61) | TRPV1ALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL10446270 | 0.74 | TRPV1 (0.47) | TRPV1SMN1; SMN2ESR1ESR2 | |
| SCHEMBL1666292 | 0.74 | TRPV1 (0.60) | TRPV1ALDH1A1HTTSMN1; SMN2KDM4E | |
| SCHEMBL1663939 | 0.74 | ESR1 (0.49) | TRPV1TP53SMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102653-B2 | Substituted quinazolinones as vanilloid antagonists | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| CN-1956721-B | Quinazolinone derivatives as vanilloid antagonists | NOVARTIS AG | 2015-05-13 | — | — | CN | disclosed |
| US-20140315932-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2014-10-23 | — | — | US | disclosed |
| US-8809528-B2 | Quinazolinone derivatives useful as vanilloid antagonists | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-20120184571-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG | 2012-07-19 | — | — | US | disclosed |
| US-8211902-B2 | Quinazolinone derivatives useful as vanilloid antagonists | NOVARTIS AG (CH) | 2012-07-03 | — | — | US | disclosed |
| US-20110195983-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG | 2011-08-11 | — | — | US | disclosed |
| EP-1755606-B2 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| US-7960399-B2 | Quinazolinone derivatives useful as vanilloid antagonists | NOVARTIS AG (CH) | 2011-06-14 | — | — | US | disclosed |
| EP-2305652-A2 | Trisubstituted quinazolinone derivatives as vanilloid antagonists | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-1978967-A1 | QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2008-10-15 | — | — | EP | disclosed |
| EP-1963283-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| US-20080194595-A1 | Bone disorders; osteoporosis; analgesics; muscular disorders; inflammatory bowel disorders | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2008-08-14 | — | — | US | disclosed |
| EP-1755606-B1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-10-31 | — | — | EP | disclosed |
| WO-2007065662-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065663-A1 | QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065663-A1 | QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| CN-1956721-A | Quinazolinone derivatives as vanilloid antagonists | NOVARTIS AG (CH) | 2007-05-02 | — | — | CN | disclosed |
| EP-1755606-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005120510-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194595-A1 | Bone disorders; osteoporosis; analgesics; muscular disorders; inflammatory bowel disorders | CACNA1A, ALPI, CACNA1E | NPC1 3713/4885TRPV1 57/4885TP53 4694/4885 |
| US-20140315932-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | TRPV1, TRPV3, CACNA1A | NPC1 1954/4885TRPV1 1/4885TP53 3609/4885 |
| US-20110195983-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | TRPV1, TRPV3, TRPV5 | NPC1 1324/4885TRPV1 1/4885TP53 3846/4885 |
| US-20120184571-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | TRPV1, TRPV3, TRPV5 | NPC1 1324/4885TRPV1 1/4885TP53 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.